Moody National Bank Trust Division Grows Position in Repligen Co. (NASDAQ:RGEN)

Moody National Bank Trust Division raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 10.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,591 shares of the biotechnology company’s stock after purchasing an additional 147 shares during the period. Moody National Bank Trust Division’s holdings in Repligen were worth $229,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of RGEN. Acadian Asset Management LLC purchased a new position in shares of Repligen in the 2nd quarter worth about $157,000. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 89 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Repligen by 16.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 19,574 shares of the biotechnology company’s stock worth $2,467,000 after purchasing an additional 2,783 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in Repligen by 0.7% in the second quarter. Envestnet Asset Management Inc. now owns 108,741 shares of the biotechnology company’s stock valued at $13,708,000 after buying an additional 741 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 0.5 %

RGEN opened at $157.29 on Thursday. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.81 billion, a PE ratio of -425.10, a P/E/G ratio of 4.64 and a beta of 0.97. The firm’s fifty day moving average price is $147.58 and its 200 day moving average price is $144.08.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 EPS. As a group, research analysts expect that Repligen Co. will post 1.54 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $185.20.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.